Evidence map›Paper›PMID 27820605›Full record

ArticleNature medicine2016

Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.

Jiwon Lee, Daniel R Boutz, Veronika Chromikova, M Gordon Joyce, Christopher Vollmers, Kwanyee Leung, Andrew P Horton, Brandon J DeKosky, Chang-Han Lee, Jason J Lavinder and 25 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02987374 (Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization), which is not on this map. Cited by 194 papers.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed
31.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02987374 phase4completednot on this map

Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization

TypeinterventionalSponsorStanford UniversityRan2012 to 2012Enrolled10ConditionsInfluenzaArms2011-2012 Fluzone IIV3 (IM)
3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 302 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Observational

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 9 institutions in 1 country.

Jiwon LeeDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
Daniel R BoutzCenter for Systems and Synthetic Biology, University of Texas at Austin, Austin, Texas, USA.
Veronika ChromikovaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
M Gordon JoyceVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Christopher VollmersDepartment of Bioengineering, Stanford University, Stanford, California, USA.
Kwanyee LeungVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Andrew P HortonCenter for Systems and Synthetic Biology, University of Texas at Austin, Austin, Texas, USA.
Brandon J DeKoskyDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
Chang-Han LeeDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
Jason J LavinderDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
Ellen M MurrinDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
Constantine ChrysostomouDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
Kam Hon HoiDepartment of Biomedical Engineering, University of Texas at Austin, Austin, Texas, USA.
Yaroslav TsybovskyElectron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Paul V ThomasVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Aliaksandr DruzVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Baoshan ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Yi ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Lingshu WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Wing-Pui KongVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Daechan ParkDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
Lyubov I PopovaDepartment of Medicine, Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA.
Cornelia L DekkerDepartment of Pediatrics, Stanford University, Stanford, California, USA.
Mark M DavisHoward Hughes Medical Institute, Stanford University, Stanford, California, USA.
Chalise E CarterCenter for Vaccines and Immunology, Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
Ted M RossCenter for Vaccines and Immunology, Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
Andrew D EllingtonCenter for Systems and Synthetic Biology, University of Texas at Austin, Austin, Texas, USA.
Patrick C WilsonDepartment of Medicine, Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA.
Edward M MarcotteCenter for Systems and Synthetic Biology, University of Texas at Austin, Austin, Texas, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Gregory C IppolitoDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Stephen R QuakeDepartment of Bioengineering, Stanford University, Stanford, California, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
George GeorgiouDepartment of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA.
The University of Texas at Austin · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USStanford University · USIcahn School of Medicine at Mount Sinai · USUniversity of Chicago · USUniversity of Georgia · USHoward Hughes Medical Institute · USLeidos (United States) · US

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Targeting Dendritic Cells for Enhanced Musocal ImmunityU19AI057234 · NIAID · BAYLOR RESEARCH INSTITUTE · PI LEGRAND, ROGER · 2003 to 2013
$49.2M
Virology CoreP01AI089618 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Jiwon Lee · 2011 to 2026
$40.0M
Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1UL1RR025744 · NCRR · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2008 to 2011
$22.4M
Understanding Human B Cell Responses to Influenza to Improve the Influenza U19AI109946 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RAVETCH, JEFFREY VICTOR · 2014 to 2018
$9.6M
University of Chicago Autoimmunity Center of ExcellenceU19AI082724 · NIAID · UNIVERSITY OF CHICAGO · PI CLARK, MARCUS RAMSAY · 2009 to 2023
$7.2M
Computational Tools for Structural AnalysisZICAI005112 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAWI, REDA · 2010 to 2025
$4.1M
Computational Algorithms, Methods, and Tools for Structure-Based Vaccine DesignZICAI005113 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KWONG, PETER D · 2010 to 2019
$2.5M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCRR NIH HHS UL1 RR025744NIAID NIH HHS HHSN272201400005CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS P01 AI089618NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI057234NIAID NIH HHS U19 AI082724NIAID NIH HHS U19 AI109946
6 · The paper itself

Abstract

Molecular understanding of serological immunity to influenza has been confounded by the complexity of the polyclonal antibody response in humans. Here we used high-resolution proteomics analysis of immunoglobulin (referred to as Ig-seq) coupled with high-throughput sequencing of transcripts encoding B cell receptors (BCR-seq) to quantitatively determine the antibody repertoire at the individual clonotype level in the sera of young adults before and after vaccination with trivalent seasonal influenza vaccine. The serum repertoire comprised between 40 and 147 clonotypes that were specific to each of the three monovalent components of the trivalent influenza vaccine, with boosted pre-existing clonotypes accounting for ∼60% of the response. An unexpectedly high fraction of serum antibodies recognized both the H1 and H3 monovalent vaccines. Recombinant versions of these H1 + H3 cross-reactive antibodies showed broad binding to hemagglutinins (HAs) from previously circulating virus strains; several of these antibodies, which were prevalent in the serum of multiple donors, recognized the same conserved epitope in the HA head domain. Although the HA-head-specific H1 + H3 antibodies did not show neutralization activity in vitro, they protected mice against infection with the H1N1 and H3N2 virus strains when administered before or after challenge. Collectively, our data reveal unanticipated insights regarding the serological response to influenza vaccination and raise questions about the added benefits of using a quadrivalent vaccine instead of a trivalent vaccine.

Indexed as

AdultAnimalsAntibodies, ViralB-LymphocytesChromatography, LiquidCross ReactionsEpitopesFemaleHemagglutinin Glycoproteins, Influenza VirusHigh-Throughput Nucleotide SequencingHumansImmunogenicity, VaccineImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin GInfluenza VaccinesReceptors, Antigen, B-CellRNA, Messenger

Identifiers

PMID27820605
PMCPMC5301914
OpenAlexW2551492487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.